Centene stock reflects its latest earnings and market backdrop.

Centene Corp. (US15133V1035) remains tied to a large managed-care base, with 2025 revenue of $163.1 billion and adjusted diluted EPS of $6.86 reported for the year. The company also ended 2025 with $20.7 billion of cash and investments, a balance sheet metric that matters for a Medicaid-heavy insurer.

2025 revenue still sets the tone

Centene reported 2025 premium and service revenue of $160.7 billion, while total revenue reached $163.1 billion for the year. That scale makes the company one of the biggest U.S. health insurers, and the 2025 figures provide the core comparison point for 2026 trading.

Adjusted diluted EPS of $6.86 in 2025 gives investors a clear earnings reference, while the companys 2025 net cash from operating activities remained central to its funding capacity. Centene also reported $20.7 billion in cash and investments at year-end 2025, a number that frames liquidity alongside earnings quality.

Margins and capital matter

Centene said its 2025 health benefits ratio and administrative cost structure were shaped by Medicaid, Medicare and Marketplace membership, which is why the business remains sensitive to state and federal program changes. The companys 2025 results also included a large revenue base against which any margin shift will be measured in 2026.

For investors, the key issue is less the absolute size of the company than the durability of those 2025 earnings metrics. A business that produced $163.1 billion of revenue and $6.86 of adjusted EPS in one year gives the market a concrete benchmark for any 2026 reset.

Medicaid drives the product mix

Centene's main insurance products are Medicaid, Medicare and Marketplace plans, with Medicaid remaining the most important volume driver. That product mix explains why the companys reported 2025 revenue and cash figures matter more than a generic health-care profile.

The companys scale is also visible in its membership base, which spans tens of millions of customers across government-sponsored and commercial coverage lines. That breadth is what makes the 2025 figures relevant to the next reporting cycle.

Nasdaq context frames the shares

Centene stock trades on Nasdaq under the symbol CNC, and the market typically treats annual revenue, adjusted EPS and liquidity as the main reference points for valuation. The 2025 metrics - $163.1 billion in revenue, $6.86 in adjusted diluted EPS and $20.7 billion in cash and investments - remain the cleanest evidence set for the stock narrative.

Without a fresh price print in the available material, the most useful market anchor is the earnings base itself. For a health insurer of this size, the 2025 numbers are the level investors compare against any later 2026 update.

Dividend and balance sheet

Centene has not built its equity story around a large cash dividend; instead, the market usually focuses on earnings, membership and capital. That makes the 2025 cash and investments figure of $20.7 billion especially relevant when assessing financial flexibility.

The 2025 adjusted EPS of $6.86 also gives a simple yardstick for future guidance, especially if management updates margins, medical costs or membership assumptions in 2026.

Centene product mix

Centene's representative product line is Medicaid managed care, supported by Medicare and Marketplace coverage. That mix is the reason the companys annual revenue and earnings metrics are watched so closely in relation to policy and membership trends.

Centene stock on Nasdaq

Centene stock is listed on Nasdaq under CNC, and the stock story is anchored by the 2025 revenue figure of $163.1 billion, adjusted diluted EPS of $6.86 and year-end cash and investments of $20.7 billion. Those numbers define the companys current valuation backdrop more clearly than any generic description of the business.